Anavex Life Sciences Corp. (LON:0HFR)

Anavex Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	101.16	132.19	151.02	149.16	152.11	29.25
Cash & Short-Term Investments	101.16	132.19	151.02	149.16	152.11	29.25
Cash Growth	-27.09%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Other Receivables	0.82	2.45	2.71	3.19	9.14	4.85
Receivables	0.82	2.45	2.71	3.19	9.14	4.85
Prepaid Expenses	0.45	0.93	0.65	0.35	0.37	0.44
Total Current Assets	102.43	135.57	154.39	152.71	161.62	34.54
Total Assets	102.43	135.57	154.39	152.71	161.62	34.54
Accounts Payable	6.74	9.63	4.32	3.83	4.74	3.99
Accrued Expenses	3.93	4.84	7.3	5.95	5.61	3.32
Current Unearned Revenue	0.81	0.84	0.92	0.44	0.44	-
Total Current Liabilities	11.47	15.3	12.53	10.21	10.8	7.31
Total Liabilities	11.47	15.3	12.53	10.21	10.8	7.31
Common Stock	0.09	0.09	0.08	0.08	0.08	0.06
Additional Paid-In Capital	463.49	456.25	434.84	387.98	348.33	186.85
Retained Earnings	-372.62	-336.07	-293.07	-245.56	-197.59	-159.68
Shareholders' Equity	90.96	120.26	141.85	142.49	150.82	27.24
Total Liabilities & Equity	102.43	135.57	154.39	152.71	161.62	34.54
Net Cash (Debt)	101.16	132.19	151.02	149.16	152.11	29.25
Net Cash Growth	-27.09%	-12.47%	1.25%	-1.94%	420.04%	31.84%
Net Cash Per Share	1.19	1.58	1.89	1.94	2.18	0.50
Filing Date Shares Outstanding	85.89	84.82	82.09	77.96	76.02	66.96
Total Common Shares Outstanding	85.41	84.8	82.07	77.94	75.92	62.05
Working Capital	90.96	120.26	141.85	142.49	150.82	27.24
Book Value Per Share	1.06	1.42	1.73	1.83	1.99	0.44
Tangible Book Value	90.96	120.26	141.85	142.49	150.82	27.24
Tangible Book Value Per Share	1.06	1.42	1.73	1.83	1.99	0.44

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.